Decatenation checkpoint-defective melanomas are dependent on PI3K for survival

Area of Science:

• Cell Biology
• Cancer Research
• Molecular Biology

Background:

• Melanoma often exhibits defects in the G2-phase cell cycle checkpoint, which monitors chromosome structure after replication.
• This checkpoint defect typically involves the response to incomplete chromosome catenation.

Purpose of the Study:

• To investigate the compensatory mechanisms in melanomas with defective G2 checkpoints.
• To identify molecular targets that can be exploited therapeutically in these melanoma cells.

Main Methods:

• Utilized an siRNA kinome screen to identify kinases involved in checkpoint adaptation.
• Assessed sensitivity of checkpoint-defective melanoma cells to PI3K pathway inhibitors.
• Measured apoptosis induction and levels of activated Akt in response to PI3K inhibition.

Main Results:

• Melanoma cells with defective G2 checkpoints showed reduced sensitivity to genotoxic stress, indicating enhanced DNA damage tolerance.
• An siRNA screen identified PI3K pathway components as crucial for this adaptation.
• Checkpoint-defective cell lines were three times more sensitive to PI3K inhibitors, with PF-05212384 inducing apoptosis.
• Increased sensitivity correlated with elevated levels of activated Akt.

Conclusions:

• Increased PI3K pathway activation is a critical adaptation enabling survival in melanomas lacking a functional decatenation checkpoint.
• Targeting the PI3K pathway represents a promising therapeutic strategy for melanomas with defective G2 checkpoints.